Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Abstract

Apurva A. Patel

Ananya Pareek

Background Immunotherapy is a proven therapeutic option in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum therapy. At present, there are no published Indian data regarding administration of nivolumab in this setting.

Aim The aim of this study is to retrospectively evaluate the efficacy and toxicity of nivolumab in R/M HNSCC among Indian patients who progressed after one or more lines of chemotherapy, including platinum agents.

Methods All patients of R/M HNSCC who received nivolumab between 2/6/2018 to 31/3/2020 were assessed retrospectively for the efficacy and toxicity of nivolumab therapy.

Statistical Analysis All the data analysis was performed using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, N.Y., USA). Descriptive analysis was performed to obtain baseline characteristic of the study sample. Survival analysis was done using the Kaplan–Meier method.

Results Nivolumab therapy was tolerated well, with no new safety concerns, except one (8.3%) patient experienced grade ¾ toxicity (gastrointestinal). The clinical benefit rate (CBR) was found to be 66.7%. The median progression-free survival (PFS) was 3 months (95% CI; 2.093–3.907), and median overall survival (OS) was 8 months (95% CI; 3.731–12.269) from the date of first dose of nivolumab.

Conclusions In our study, efficacy and toxicity were comparable with international data with no new safety concerns. Nivolumab emerged as an astonishing treatment option with tolerable toxicity profile in patients with R/M HNSCC postplatinum therapy, although limited treatment options are available at present.

Keywords

nivolumab - recurrent - metastatic - efficacy - toxicity

Publikationsverlauf

Artikel online veröffentlicht:
31. Dezember 2021

• References

• 1 Dar MA, Sharma KK. Burden of cancer in India: GLOBOCAN 2018 Estimates Incidence, Mortality, prevalence and future projections of cancer in India. Burden Cancer India 2019; 6: 505-514
• 2 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer 2012
• 3 Bernier J. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol 2008; 5 (12) 705-713
• 4 Saloura V, Cohen EE, Licitra L. et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014; 73 (06) 1227-1239
• 5 Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015; 33 (29) 3293-3304
• 6 Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol 2017; 44 (02) 136-140
• 7 Ferris RL, Blumenschein Jr G, Fayette J. et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81: 45-51
• 8 Verma V, Sprave T, Haque W. et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer 2018; 6 (01) 128
• 9 Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Role of immunotherapy in head and neck cancer. Semin Radiat Oncol 2018; 28 (01) 12-16
• 10 de Ruiter EJ, Ooft ML, Devriese LA, Willems SM. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. OncoImmunology 2017; 6 (11) e1356148
• 11 Kareemaghay S, Tavassoli M. Clinical immunotherapeutic approaches for the treatment of head and neck cancer. Int J Oral Maxillofac Surg 2019; 48 (04) 419-436
• 12 Dong M, Meng Z, Kuerban K. et al. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell Death Dis 2018; 9 (10) 1039
• 13 Pichler R, Loidl W, Pichler M. High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer. Transl Androl Urol 2018; 7 (Suppl. 06) S738-S740
• 14 Haanen JBAG, Carbonnel F, Robert C. et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv119-iv142
• 15 Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (02) 123-135
• 16 Gupta VG, Rangaraju RR, Abbas W, Bajpai P, Khetrapal R. Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. South Asian J Cancer 2019; 8 (01) 65-68
• 17 Ferris RL, Blumenschein Jr G, Fayette J. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375 (19) 1856-1867
• 18 Garon EB, Rizvi NA, Hui R. et al. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21) 2018-2028
• 19 El Rassy E, Assi T, Bakouny Z, El Karak F, Pavlidis N, Ghosn M. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Future Oncol 2019; 15 (08) 909-923
• 20 Sharma P, Retz M, Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18 (03) 312-322